-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Researchers from the Karolinska Institute in Sweden report that a recently discovered inflammatory mediator, interleukin-26, seems to play an important role in pneumonia and helps kill bacteria
.
The research was published in the journal Frontiers in Immunology-Microbial Immunology
Bacterial lung infections affect children and adults all over the world.
Pneumonia is still a common cause of premature death in many parts of the world
.
Approximately millions of people die from pneumonia each year .
This new study shows that an inflammatory mediator called interleukin-26 (IL-26) plays an important role in human bacterial pneumonia
.
As we all know, the innate immune response is our first line of defense against pathogens
.
In the past decade, IL-26 has become an important role in the innate immune response
By studying the lung tissue and airway samples of patients with bacterial pneumonia, researchers found that IL-26 has a complex regulatory effect on the immune system.
This protein can directly kill the bacteria known to cause pneumonia-Klebsiella pneumonia ( Klebsiella pneumoniae )
Karlhans Che of the Institute of Environmental Medicine of the Karolinska Institute said: "Antibiotics are not enough to treat pneumonia, and drug resistance is an increasingly serious problem, which highlights the need for biological treatment of this deadly disease
.
Our research It was found that IL-26 showed diagnostic and therapeutic potential in pneumonia, and emphasized that its role in pneumonia deserves further evaluation
This research was funded by the Swedish Heart and Lung Foundation, the Swedish Research Council, the Stockholm Region (ALF Fund) and the Swedish Medical Research Association
.
The author declares that there is no conflict of interest
###
"Complex Involvement of Interleukin-26 in Bacterial Lung Infection".
Karlhans F.
Che, Magnus Paulsson, Krzysztof Piersiala, Jakob Sax, Ibrahim Mboob, Mizanur Rahman, Rokeya S.
Rekha, Jesper Säfholm, Mikael Adner, Peter Bergman, Cardell, Kristian Riesbeck, Anders Lindén.
Frontiers in Immunology-Microbial Immunology, online 28 October 2021, doi: 10.
3389/fimmu.
